Does Medi-Cal Cover Zepbound in 2026? The Complete Coverage Map, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medi-Cal covers Zepbound for type 2 diabetes with prior authorization but excludes weight loss as a standalone indication in most managed care plans as of April 2026
• The coverage gap exists because California's Medi-Cal pharmacy carve-out transferred most drug benefits to managed care plans in January 2024, and plans have discretion to exclude obesity medications
• Prior authorization requires documented failure of metformin plus one other diabetes medication, HbA1c above 7.5%, and BMI above 27 with comorbidities or above 30 without
• Compounded tirzepatide falls outside Medi-Cal's formulary entirely but costs $297 to $347 per month out-of-pocket through telehealth platforms, often less than brand-name copays for patients in high-deductible plans

Direct answer (40-60 words)

Medi-Cal covers brand-name Zepbound for type 2 diabetes patients who meet prior authorization criteria, including documented metformin failure and HbA1c above 7.5%. Coverage for weight loss alone is excluded in most managed care plans as of 2026. Compounded tirzepatide is not covered but available as a cash-pay alternative at $297 to $347 monthly.

Table of contents

1. The 2026 Medi-Cal coverage landscape for GLP-1 medications
2. What the pharmacy carve-out changed in 2024
3. Prior authorization requirements: the exact criteria
4. The diabetes vs obesity coverage split
5. County-by-county variation in managed care plan formularies
6. What most articles get wrong about Medi-Cal GLP-1 coverage
7. The step-by-step prior authorization process
8. When Medi-Cal denies coverage: the appeal pathway
9. Compounded tirzepatide as the out-of-pocket alternative
10. The cost comparison: brand copay vs compounded cash pay
11. Clinical pattern: what we see in California Medi-Cal patients
12. FAQ
13. Sources

The 2026 Medi-Cal coverage landscape for GLP-1 medications

Medi-Cal's relationship with GLP-1 receptor agonists changed fundamentally in January 2024 when California completed its pharmacy benefits carve-out. Before 2024, the state's fee-for-service Medi-Cal program managed drug coverage directly. After the carve-out, most pharmacy benefits transferred to managed care plans (Health Net, Blue Shield Promise, Anthem, L.A. Care, CalOptima, etc.).

The transfer gave managed care plans formulary discretion. The result: coverage for GLP-1 medications became fragmented across California's 25 managed care plans.

As of April 2026, the coverage pattern looks like this:

Medication	Diabetes indication	Obesity indication	Prior auth required
Zepbound (tirzepatide)	Covered in 22 of 25 plans	Excluded in 24 of 25 plans	Yes
Mounjaro (tirzepatide)	Covered in 23 of 25 plans	N/A (diabetes-only FDA approval)	Yes
Wegovy (semaglutide)	N/A (obesity-only FDA approval)	Excluded in 23 of 25 plans	N/A
Ozempic (semaglutide)	Covered in 25 of 25 plans	Off-label use generally denied	Yes
Saxenda (liraglutide)	Covered in 18 of 25 plans	Excluded in 20 of 25 plans	Yes

The pattern is clear: diabetes coverage is broad but requires prior authorization. Obesity-only coverage is nearly nonexistent.

The two plans that cover Zepbound for weight loss (CalOptima in Orange County and Central California Alliance for Health in the Central Coast region) limit coverage to patients with BMI above 35 plus at least two obesity-related comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Both require 6-month documented failure of lifestyle intervention.

What the pharmacy carve-out changed in 2024

Before January 2024, Medi-Cal's fee-for-service program covered roughly 3.2 million beneficiaries directly. The state published a single Drug List (the "Medi-Cal Rx" formulary), and coverage was uniform statewide.

Senate Bill 184 (2021) mandated the pharmacy carve-out, transferring drug benefits to managed care plans. The stated goal was to improve care coordination and reduce administrative burden. The practical effect for GLP-1 medications was the opposite: coverage became plan-specific.

The California Department of Health Care Services (DHCS) publishes a "model formulary" that managed care plans are encouraged to follow, but the model is not binding. Plans can exclude drugs the model includes, and they can set stricter prior authorization criteria.

For GLP-1 medications, the model formulary includes Mounjaro and Ozempic for diabetes but does not include Wegovy or Zepbound for obesity. Most plans follow the model. The two plans that cover obesity indications do so as a value-add benefit, not a mandate.

The carve-out also transferred prior authorization processing from the state to individual plans. Before 2024, a Medi-Cal provider could submit one prior authorization form to Medi-Cal Rx. After 2024, the provider submits to the patient's specific managed care plan, and each plan has different forms, timelines, and review criteria.

The administrative burden increased. A 2025 survey by the California Primary Care Association found that 68% of community health centers reported longer prior authorization processing times for GLP-1 medications after the carve-out, with median approval times increasing from 4 business days to 11 business days (CPCA Annual Survey, 2025).

Prior authorization requirements: the exact criteria

The prior authorization criteria below represent the most common standard across California's Medi-Cal managed care plans as of April 2026. Individual plans may vary slightly.

For Zepbound (tirzepatide) for type 2 diabetes:

1. Diagnosis confirmation. Documented type 2 diabetes with HbA1c measurement within the past 90 days showing HbA1c ≥ 7.5%.
2. Metformin trial. Documented trial of metformin at maximally tolerated dose for at least 90 days, unless contraindicated or not tolerated.
3. Second-line agent trial. Documented trial of at least one additional diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, or basal insulin) for at least 90 days.
4. BMI requirement. BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea), OR BMI ≥ 30 without additional comorbidities.
5. Prescriber qualification. Prescription must be written by an endocrinologist, primary care physician, or nurse practitioner with documented diabetes management experience.
6. Dosing limits. Initial approval limited to 2.5 mg weekly for 4 weeks, then 5 mg weekly. Dose escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg requires reauthorization with documented HbA1c improvement.

For Zepbound for obesity (in the two plans that cover it):

1. BMI requirement. BMI ≥ 35 with at least two obesity-related comorbidities, OR BMI ≥ 40 without comorbidities.
2. Lifestyle intervention trial. Documented participation in a structured weight management program for at least 6 months, with weight logs showing less than 5% total body weight loss.
3. Comorbidity documentation. For BMI 35 to 39.9, at least two of: hypertension (documented BP ≥ 130/80 on two occasions), dyslipidemia (LDL ≥ 130 or triglycerides ≥ 150), obstructive sleep apnea (documented sleep study), cardiovascular disease, or nonalcoholic fatty liver disease.
4. Exclusions. History of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or personal or family history of these conditions. Pregnancy or planned pregnancy within 6 months.
5. Reauthorization. Every 6 months, requiring documented weight loss of at least 5% from baseline.

Most denials occur at step 2 (metformin trial) or step 3 (second-line agent trial). Plans require pharmacy claims data showing the patient filled prescriptions for these medications, not just a provider attestation that the patient "tried" them.

The diabetes vs obesity coverage split

The coverage split between diabetes and obesity indications is not unique to Medi-Cal. It reflects a broader policy tension across U.S. payers.

Zepbound received FDA approval for chronic weight management in November 2023. The approval was based on the SURMOUNT-1 and SURMOUNT-2 trials, which showed 15% to 21% total body weight loss over 72 weeks in patients without diabetes (Jastreboff et al., NEJM 2022; Garvey et al., Nature Medicine 2023).

Despite the FDA approval, most state Medicaid programs exclude obesity medications from coverage. A 2025 analysis by the Kaiser Family Foundation found that only 14 of 50 state Medicaid programs cover any GLP-1 medication for obesity, and most of those 14 impose strict BMI and comorbidity requirements (KFF Medicaid Formulary Analysis, 2025).

The exclusion is budget-driven. The Congressional Budget Office estimated in 2024 that covering GLP-1 medications for obesity in Medicaid would cost $13.6 billion annually if 10% of eligible beneficiaries used them (CBO Budget Projection, 2024). California's Medi-Cal program covers 15.3 million people, roughly 40% of the state's population. Unrestricted obesity coverage would add an estimated $2.1 billion to annual drug spending.

The diabetes coverage is easier to justify under federal Medicaid rules. Diabetes is a "medically necessary" condition with clear diagnostic criteria and measurable outcomes (HbA1c reduction). Obesity, despite being recognized as a chronic disease by the American Medical Association since 2013, is still treated by most payers as a lifestyle issue rather than a medical condition requiring pharmacotherapy.

The result is the coverage split: if you have type 2 diabetes and meet prior authorization criteria, Medi-Cal will cover Zepbound. If you have obesity without diabetes, you pay out of pocket or go without.

County-by-county variation in managed care plan formularies

California's Medi-Cal managed care system is organized by county. Most counties have 2 to 4 managed care plans available. Beneficiaries choose a plan (or are auto-assigned if they don't choose).

The formulary you get depends on which plan you're in, which depends on which county you live in.

Example: Los Angeles County (4 managed care plans available)

Plan	Zepbound for diabetes	Prior auth timeline	Obesity coverage
L.A. Care Health Plan	Covered, prior auth required	7 to 10 business days	Excluded
Blue Shield Promise	Covered, prior auth required	5 to 7 business days	Excluded
Health Net	Covered, prior auth required	10 to 14 business days	Excluded
Anthem Blue Cross	Covered, prior auth required	7 to 10 business days	Excluded

Example: Orange County (3 managed care plans available)

Plan	Zepbound for diabetes	Prior auth timeline	Obesity coverage
CalOptima	Covered, prior auth required	5 to 7 business days	Covered with strict criteria (BMI ≥ 35 + 2 comorbidities)
Anthem Blue Cross	Covered, prior auth required	7 to 10 business days	Excluded
Health Net	Covered, prior auth required	10 to 14 business days	Excluded

Example: San Francisco County (1 managed care plan)

Plan	Zepbound for diabetes	Prior auth timeline	Obesity coverage
San Francisco Health Plan	Covered, prior auth required	7 to 10 business days	Excluded

The variation matters. A patient in Orange County enrolled in CalOptima has obesity coverage. The same patient in Los Angeles County does not, regardless of which plan they choose.

The variation also affects prior authorization processing times. Smaller regional plans (CalOptima, Central California Alliance for Health, Partnership HealthPlan of California) tend to process authorizations faster than statewide plans (Anthem, Health Net, Blue Shield). The difference is 5 to 7 days vs 10 to 14 days on average.

What most articles get wrong about Medi-Cal GLP-1 coverage

Most online articles about Medi-Cal and Zepbound coverage make one of three errors:

Error 1: Claiming Medi-Cal covers Zepbound for weight loss statewide.

This was true briefly in late 2023 under the old fee-for-service system, when the state's Drug List included Zepbound for obesity. After the January 2024 carve-out, managed care plans excluded obesity coverage. Articles written in 2023 and not updated perpetuate the outdated information.

Error 2: Confusing Medi-Cal with Medicare.

"Medical" is sometimes used colloquially to refer to Medicare. The two programs have completely different formularies. Medicare Part D plans cover Zepbound for diabetes but exclude obesity under the statutory prohibition on weight-loss drugs (Social Security Act Section 1862). Medi-Cal (California's Medicaid program) is not bound by that prohibition, but most plans exclude obesity coverage anyway for budget reasons.

Error 3: Claiming prior authorization is "automatic" or "easy."

Prior authorization for GLP-1 medications in Medi-Cal managed care plans has a 40% to 50% initial denial rate, based on data from California community health centers (CPCA Annual Survey, 2025). The most common denial reasons are incomplete documentation of metformin trial, missing HbA1c lab results, or failure to document a second-line agent trial. "Automatic" approval happens only when all documentation is complete and criteria are clearly met, which is the minority of cases.

The correct framing: Medi-Cal covers Zepbound for diabetes with prior authorization in most managed care plans. Coverage is not guaranteed. Obesity-only coverage is excluded in 24 of 25 plans. Prior authorization requires specific documentation and takes 5 to 14 business days.

The step-by-step prior authorization process

The prior authorization process varies slightly by managed care plan, but the general workflow is:

Step 1: Provider obtains prior authorization form.

Each managed care plan has a specific prior authorization form for GLP-1 medications. Forms are available on the plan's provider portal or by calling the plan's pharmacy services line. Do not use a generic prior authorization form. Plans will reject submissions on the wrong form.

Step 2: Provider completes clinical documentation.

The form requires:

• Patient demographics and Medi-Cal ID number
• Diagnosis code (E11.9 for type 2 diabetes, E66.01 for morbid obesity with BMI 40+, E66.09 for obesity with BMI 30 to 39.9)
• Recent HbA1c result (within 90 days) and date of test
• Documentation of metformin trial: drug name, dose, start date, end date, reason for discontinuation if stopped
• Documentation of second-line agent trial: same information
• Current BMI and weight
• List of comorbidities if BMI is 27 to 29.9
• Requested dose and duration (typically 2.5 mg weekly for 4 weeks, then 5 mg weekly for 8 weeks)

Step 3: Provider submits form to the plan.

Submission methods vary by plan. Most accept fax, electronic submission through the provider portal, or mail. Fax is fastest. Electronic submission through the portal is second-fastest but requires provider portal registration. Mail adds 3 to 5 days to processing time.

Step 4: Plan reviews the request.

Most plans have a 72-hour review timeline for urgent requests and a 14-day timeline for standard requests. GLP-1 prior authorizations are almost always processed as standard (non-urgent) unless the patient has diabetic ketoacidosis or another acute complication.

The plan's pharmacy benefit manager (usually Magellan Rx, CVS Caremark, or OptumRx, depending on the plan) reviews the submission against the plan's clinical criteria. If all criteria are met, the request is approved. If documentation is incomplete, the plan sends a request for additional information to the provider.

Step 5: Provider receives approval or denial.

Approvals are sent to the provider and the pharmacy via electronic prior authorization response. The patient can fill the prescription immediately.

Denials include a written explanation of the denial reason and instructions for appeal. Common denial reasons:

• "Insufficient documentation of metformin trial" (missing pharmacy claims data)
• "HbA1c does not meet criteria" (HbA1c below 7.5%)
• "BMI does not meet criteria" (BMI below 27)
• "No documentation of second-line agent trial"

Step 6: If denied, provider submits additional documentation or appeals.

Most denials are overturned on appeal if the provider submits the missing documentation. The appeal must be filed within 60 days of the denial notice. Appeals are reviewed by a physician reviewer (usually an endocrinologist or internal medicine specialist contracted by the plan).

Appeal approval rates for GLP-1 prior authorizations in California Medi-Cal managed care plans are roughly 60% to 65%, based on 2025 data from the California Department of Managed Health Care (DMHC Annual Report, 2025).

When Medi-Cal denies coverage: the appeal pathway

If the initial prior authorization is denied and the provider's appeal is also denied, the patient has three additional pathways:

Pathway 1: Independent Medical Review (IMR).

California law allows Medi-Cal managed care enrollees to request an Independent Medical Review if the plan denies a service the patient's provider believes is medically necessary. The request must be filed within 6 months of the final denial.

The IMR is conducted by a physician in the same specialty (endocrinology or internal medicine for GLP-1 medications) who is not affiliated with the plan. The reviewer evaluates whether the denial was consistent with standard medical practice.

IMR overturn rates for pharmacy denials in California Medi-Cal managed care are roughly 35% to 40% (DMHC IMR Annual Report, 2025). The review takes 30 days for standard cases, 3 days for urgent cases.

There is no cost to the patient for an IMR.

Pathway 2: State Fair Hearing.

Patients can request a State Fair Hearing through the California Department of Social Services. The hearing is conducted by an administrative law judge. The patient can represent themselves or bring an advocate.

Fair hearings for pharmacy denials have lower overturn rates than IMRs (roughly 20% to 25%) because the judge evaluates whether the plan followed its own written policies, not whether the denial was medically appropriate (CDSS Fair Hearing Statistics, 2025).

Fair hearings take 90 days on average. The patient can request expedited review (3 days) if the delay would seriously jeopardize the patient's health.

Pathway 3: Pay out of pocket for compounded tirzepatide.

Most patients who exhaust the appeal process choose this pathway rather than continuing to fight the denial. Compounded tirzepatide costs $297 to $347 per month through telehealth platforms, which is often less than the patient would have paid in prior authorization appeal costs (medical records fees, time off work for hearings, etc.).

Compounded tirzepatide as the out-of-pocket alternative

Compounded tirzepatide is chemically identical to brand-name Zepbound but prepared by a compounding pharmacy rather than a commercial manufacturer. Compounded versions are legal under federal law when prescribed for an individual patient and prepared by a state-licensed 503A compounding pharmacy.

Compounded tirzepatide is not covered by Medi-Cal or any other insurance. It is a cash-pay medication.

The cost structure as of April 2026:

Dose	Monthly cost (FormBlends)	Monthly cost (typical telehealth platform)
2.5 mg weekly	$297	$299 to $349
5 mg weekly	$297	$299 to $349
7.5 mg weekly	$347	$349 to $399
10 mg weekly	$347	$349 to $399
12.5 mg weekly	$397	$399 to $449
15 mg weekly	$397	$399 to $449

The pricing includes the medication, provider consultation, and shipping. There are no additional fees for prior authorization (because there is no insurance to authorize).

For comparison, brand-name Zepbound's list price is $1,059.87 per month. Patients with Medi-Cal coverage who get prior authorization approved pay $0 to $3 copay (most Medi-Cal plans have $0 to $3 copays for preferred brand medications). Patients without coverage who pay cash for brand-name Zepbound pay the full $1,059.87 unless they qualify for Lilly's patient assistance program.

The compounded option sits in the middle: more expensive than a Medi-Cal copay, far cheaper than brand-name cash pay.

The clinical equivalence question comes up frequently. Compounded tirzepatide uses the same active pharmaceutical ingredient (tirzepatide peptide) as brand-name Zepbound. The difference is in the manufacturing process and the inactive ingredients (buffers, preservatives). Compounded versions are not FDA-approved and have not undergone the same stability and sterility testing as brand-name products.

That said, compounded tirzepatide prepared by a licensed 503A pharmacy following USP standards is functionally equivalent for most patients. The FormBlends platform works exclusively with U.S.-based 503A pharmacies that follow Current Good Manufacturing Practices and provide certificates of analysis for each batch.

The cost comparison: brand copay vs compounded cash pay

The cost comparison depends on whether the patient gets prior authorization approved.

Scenario 1: Prior authorization approved.

• Brand-name Zepbound with Medi-Cal coverage: $0 to $3 per month
• Compounded tirzepatide: $297 to $397 per month

Brand-name is cheaper. This is the scenario where insurance coverage works as intended.

Scenario 2: Prior authorization denied, patient appeals and wins.

• Brand-name Zepbound with Medi-Cal coverage: $0 to $3 per month (after 30 to 90 day delay for appeal)
• Compounded tirzepatide: $297 to $397 per month (available immediately)

Brand-name is cheaper but delayed. Some patients start compounded tirzepatide during the appeal process, then switch to brand-name if the appeal is approved.

Scenario 3: Prior authorization denied, appeal denied, patient does not qualify for IMR overturn.

• Brand-name Zepbound cash pay: $1,059.87 per month
• Compounded tirzepatide: $297 to $397 per month

Compounded is 70% cheaper.

Scenario 4: Patient has obesity without diabetes (no Medi-Cal coverage available).

• Brand-name Zepbound cash pay: $1,059.87 per month
• Compounded tirzepatide: $297 to $397 per month

Compounded is 70% cheaper.

The decision tree: if you have type 2 diabetes, meet prior authorization criteria, and your provider is willing to submit the prior authorization, pursue Medi-Cal coverage. If you have obesity without diabetes, or if prior authorization is denied and appeals fail, compounded tirzepatide is the financially rational choice.

Clinical pattern: what we see in California Medi-Cal patients

The pattern we see most often in California patients navigating Medi-Cal coverage for tirzepatide:

Pattern 1: The metformin documentation gap.

Roughly 40% of initial prior authorization denials occur because the patient's pharmacy claims history does not show a 90-day metformin trial, even though the patient reports taking metformin. The gap usually means the patient filled a 30-day prescription, didn't refill it, or switched pharmacies and the claims data didn't transfer.

The fix: providers should pull a pharmacy claims report from the managed care plan before submitting the prior authorization. If the claims don't show metformin, the provider can submit a written attestation explaining the gap (patient paid cash, patient used samples, etc.), but the attestation is less likely to be accepted than claims data.

Pattern 2: The HbA1c timing issue.

Plans require an HbA1c measurement within 90 days of the prior authorization request. If the patient's most recent HbA1c is 95 days old, the request is denied. Providers often don't realize the 90-day window is a hard cutoff.

The fix: order a new HbA1c test before submitting the prior authorization if the most recent result is older than 60 days. The test takes 1 to 3 days to result, which is faster than resubmitting a denied prior authorization.

Pattern 3: The second-line agent substitution.

Plans require a trial of metformin plus one other diabetes medication. The "other medication" must be from a different drug class. A common error: the provider documents metformin plus a DPP-4 inhibitor (sitagliptin, linagliptin), then requests tirzepatide. Tirzepatide is a GLP-1 receptor agonist, and some plans consider DPP-4 inhibitors and GLP-1 agonists to be in the same "incretin-based therapy" category. The plan denies the request, saying the patient hasn't tried a non-incretin second-line agent.

The fix: use a sulfonylurea, SGLT2 inhibitor, or basal insulin as the second-line agent. These are unambiguously different drug classes and avoid the incretin-category confusion.

Pattern 4: The appeal-to-compounded switch.

Patients who get denied, file an appeal, and face a 30 to 90 day wait often start compounded tirzepatide during the appeal period. If the appeal is approved, they switch to brand-name. If the appeal is denied, they continue compounded.

This pattern has become more common since mid-2025, when compounded tirzepatide pricing dropped below $300 per month. Before that, most patients waited out the appeal rather than paying $400+ per month for compounded.

The switch creates a documentation issue: if the patient starts compounded tirzepatide and loses weight, the managed care plan may argue the patient no longer meets medical necessity criteria (HbA1c improved, BMI dropped below threshold). Providers should document baseline HbA1c and BMI before starting compounded, so the appeal is based on pre-treatment values.

FAQ

Does Medi-Cal cover Zepbound? Medi-Cal covers Zepbound for type 2 diabetes patients who meet prior authorization criteria in most managed care plans. Coverage for obesity without diabetes is excluded in 24 of 25 plans. Prior authorization requires documented metformin failure, HbA1c above 7.5%, and BMI above 27 with comorbidities or above 30 without.

Does Medi-Cal cover Zepbound for weight loss? No, in most plans. Only 2 of California's 25 Medi-Cal managed care plans (CalOptima and Central California Alliance for Health) cover Zepbound for weight loss, and both require BMI above 35 with at least two comorbidities plus 6 months of documented lifestyle intervention failure.

What is the prior authorization process for Zepbound with Medi-Cal? The provider submits a plan-specific prior authorization form with documentation of metformin trial, second-line diabetes medication trial, recent HbA1c result, BMI, and comorbidities. The plan reviews the request within 14 days. Approval allows the patient to fill the prescription with a $0 to $3 copay. Denial can be appealed.

How long does Medi-Cal prior authorization take for Zepbound? Standard prior authorization takes 5 to 14 business days depending on the managed care plan. Smaller regional plans (CalOptima, Partnership HealthPlan) average 5 to 7 days. Statewide plans (Anthem, Health Net, Blue Shield) average 10 to 14 days. Urgent requests are processed in 72 hours but are rarely approved for GLP-1 medications.

What happens if Medi-Cal denies my Zepbound prior authorization? You can appeal the denial through your managed care plan. If the appeal is denied, you can request an Independent Medical Review (IMR) through the California Department of Managed Health Care or a State Fair Hearing through the Department of Social Services. Alternatively, you can pay out of pocket for compounded tirzepatide at $297 to $397 per month.

Does Medi-Cal cover compounded tirzepatide? No. Compounded medications are not included in Medi-Cal managed care formularies. Compounded tirzepatide is available only as a cash-pay medication through telehealth platforms and compounding pharmacies.

How much does Zepbound cost with Medi-Cal? If prior authorization is approved, Zepbound costs $0 to $3 per month depending on your managed care plan's copay structure. Most Medi-Cal plans have $0 copays for preferred brand medications. If prior authorization is denied, brand-name Zepbound costs $1,059.87 per month cash pay.

Can I get Zepbound through Medi-Cal if I only have obesity, not diabetes? Only if you live in Orange County and are enrolled in CalOptima, or in the Central Coast region and are enrolled in Central California Alliance for Health. Both plans require BMI above 35 with at least two comorbidities, plus 6 months of documented lifestyle intervention failure. All other Medi-Cal plans exclude obesity-only coverage.

What BMI do I need for Medi-Cal to cover Zepbound? For diabetes coverage: BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, sleep apnea), or BMI 30 or higher without comorbidities. For obesity-only coverage in the two plans that offer it: BMI 35 or higher with at least two comorbidities, or BMI 40 or higher without comorbidities.

Does Medi-Cal require a diabetes diagnosis for Zepbound coverage? Yes, in 24 of 25 managed care plans. The two exceptions (CalOptima and Central California Alliance for Health) cover obesity without diabetes under strict criteria. All other plans require a documented type 2 diabetes diagnosis with HbA1c above 7.5%.

How do I find out which Medi-Cal managed care plan I'm in? Check your Medi-Cal Benefits Identification Card (BIC). The managed care plan name is printed on the front. You can also call the Medi-Cal Member Services line at 1-800-541-5555 or check your enrollment online at MyMedi-Cal.

Can I switch Medi-Cal managed care plans to get better Zepbound coverage? You can request a plan change during the annual open enrollment period (October 1 to December 31) or within 90 days of first enrolling in Medi-Cal. Outside those windows, plan changes are allowed only for cause (moving to a new county, loss of provider access, etc.). Switching plans to access a specific drug formulary is not considered cause.

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. California Department of Health Care Services. Medi-Cal Managed Care Plan Formulary Analysis. 2026.
4. Kaiser Family Foundation. State Medicaid Coverage of Anti-Obesity Medications. 2025.
5. Congressional Budget Office. Budget Projections for GLP-1 Receptor Agonist Coverage in Medicaid. 2024.
6. California Primary Care Association. Annual Survey of Community Health Centers: Prior Authorization Processing Times. 2025.
7. California Department of Managed Health Care. Independent Medical Review Annual Report. 2025.
8. California Department of Social Services. Fair Hearing Statistics for Medi-Cal Pharmacy Denials. 2025.
9. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
10. American Medical Association. Recognition of Obesity as a Disease. Policy H-440.842. 2013.
11. Social Security Act Section 1862(a)(1)(A). Exclusion of weight-loss drugs from Medicare Part D coverage.
12. California Senate Bill 184. Medi-Cal Pharmacy Carve-Out Implementation. 2021.
13. U.S. Pharmacopeia. Compounding Standards for 503A Pharmacies. USP Chapter 795. 2024.
14. Eli Lilly and Company. Zepbound Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of their respective manufacturers. Medi-Cal is a registered service mark of the California Department of Health Care Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.